Treatment of chronic hepatitis B

Lancet Infectious Diseases

Volumn 1, Issue 4, 2001, Pages 232-241

  Yuen, Man Fung ^a   Lai, Ching Lung ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOLOGICAL ADJUVANT; LAMIVUDINE; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BLOOD; DRUG COMBINATION; ETHNOLOGY; FIBROSIS; HEPATITIS B; HUMAN; IMMUNOLOGY; REVIEW; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FIBROSIS; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 0035525235     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00118-9     Document Type: Review

References (52)

1. Lee W.M. Hepatitis B virus infection. N Engl J Med. 337:1997;1733-1745.
2. Yuen M.F., Lai C.L. Debates in hepatitis: how to assess HBV DNA reductions in association with therapy? Viral Hepat Rev. 5:1999;159-175.
3. Averett D.R., Mason W.S. Evaluation of drugs for antiviral activity against hepatitis B virus. Viral Hepat Rev. 1:1995;129-142.
4. Wong D.K.H., Cheung A.M., Q'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-inteferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med. 119:1993;312-323.
5. Wong J.B., Koff R.S., Tine F., Pauker S.G. Cost-effectiveness of interferon-α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 122:1995;664-675.
6. Perrillo R.P. Treatment of chronic hepatitis B with interferon: experience in western countries. Semin Liver Dis. 9:1989;240-248.
7. Lai C.L., Lok A.S.F., Lin H.J., Wu P.C., Yeoh E.K., Yeung C.Y. Placebo-controlled trial of recombinant 2-interferon in Chinese HBsAg-carrier children. Lancet. 2:1987;877-880.
8. Lai C.L., Lin H.J., Lau J.Y.N., et al. Effect of recombinant alpha-2 interferon with or without prednisone in Chinese HBsAg carrier children. QJM. 78:1991;155-163.
9. Lok A.S.F., Lai C.L., Wu P.C., Lau J.Y.N., Leung E.K.Y., Wong L.S.K. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis. 9:1989;249-253.
10. Derso A., Boxall E.H., Tarlow M.J., Flewett T.H. Transmission of HBsAg from mother to infant in four ethnic groups. BMJ. 1:1978;949-952.
11. Perrillo R.P., Schiff E.R., Davis G.L., et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal in the treatment of chronic hepatitis B. N Engl J Med. 323:1990;295-301.
12. Liaw Y.F., Liu S.M., Chan T.J., Chien R.N., Sheen I.S., Chu C.M. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. Hepatology. 20:1994;175-180.
13. Brunetto M.R., Giarin M., Saracco G., et al. Hepatitis B virus unable to secret e antigen and response to interferon in chronic hepatitis B. Gastroenterology. 105:1993;845-850.
14. Niederau C., Heintges T., Lange S., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 334:1996;1422-1427.
15. Lau D.T., Everhart J., Kleiner D.E., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 113:1997;1660-1667.
16. Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., Hoofnagle J.H. Long-term remission of chronic hepatitis B after alfa-interferon therapy. Ann Intern Med. 114:1991;629-634.
17. Lin S.M., Sheen I.S., Chien R.N., Chu C.M., Liaw Y.F. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 29:1999;975-979.
18. Yuen M.F., Hui C.K., Cheng C.C., Wu C.H., Lai Y.P., Lai C.L. Long-term follow-up of interferon-alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on HBeAg seroconversion and the development of cirrhosis-related complications. Hepatology. 34:2001;139-145.
19. Gerin J.L., Korba B.E., Cote P.J., Tennant B.C. A preliminary report of a controlled study of thymosin alfa-1 in the woodchuck model of hepadnavirus infection. Adv Exp Med Biol. 312:1992;121-123.
20. 1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody- and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology. 24:1996;774-777.
21. 1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology. 27:1998;1383-1387.
22. 1 treatment of chronic hepatitis B: a multicenter, randomized, placebo-controlled double blind study. Gastroenterology. 108:1995;A1127. (abstract).
23. Heathcote J., McHutchinson J., Lee S., et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology. 30:1999;531-536.
24. Heineman T.C., Clements-Mann M.L., Poland G.A., et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine. 17:1999;2769-2778.
25. Couillin I., Pol S., Mancini M., et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis. 180:1999;15-26.
26. Johnson M.A., Moore K.H.P., Yuen G.J., Bye A., Pakes G.E. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 26:1999;41-66.
27. Lai C.L., Yuen M.F. Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol. 61:2000;367-373.
28. Boni C., Bertoletti A., Penna A., et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 102:1998;968-975.
29. Lai C.L., Chien R.N., Leung N.W.Y., et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 339:1998;61-68.
30. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 341:1999;1256-1263.
31. Tassopoulos N.C., Volpes R., Pastore G., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology. 29:1999;889-896.
32. Lok A.S., Wu P.C., Lai C.L., et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 102:1992;2091-2097.
33. Chien R.N., Liaw Y.-F., Atkins M. The Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology. 30:1999;770-774.
34. Villeneuve J.P., Condreay L.D., Willems B., et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology. 31:2000;207-210.
35. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 34:2001;785-791.
36. Nowak M.A., Bonhoeffer S., Hill A.M., Boehme R., Thomas H.C., McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA. 93:1996;4398-4402.
37. Tsiang M., Rooney J.F., Toole J.J., Gibbs C.S. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology. 29:1999;1863-1869.
38. Leung N.W.Y., Lai C.L., Chang T.T., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 33:2001;1527-1532.
39. Allen M.I., Deslauriers M., Andrew C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1998;1670-1677.
40. Melegari M., Scaglioni P.P., Wands J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology. 27:1998;628-633.
41. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology. 120:2001;1828-1853.
42. Lai CL, Liaw YF, Leung NWY, et al. Genotypic resistance to lamivudine in a placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis infection: incidence, kinetics of emergence and correlation with disease parameters. Hepatology 1997; 26: (suppl 4 pt 2): 522A (abstract).
43. Perrillo R., Schiff E., Yoshida E., et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 32:2000;129-134.
44. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil for lamivudine resistant HBV in HIV infected patients. J Hepatol 2001; 34 (suppl 1): 1253A (abstract).
45. Yamanaka G., Wilson T., Innaimo S., et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother. 43:1999;190-193.
46. De Man R., Wolters L., Nevens F., et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B infection. Hepatology. 34:2001;578-582.
47. Bryant M.L., Bridges E.G., Placidi L., et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother. 45:2001;229-235.
48. Lim SG, Lai CL, Lee YM, Pow DM, Maureen WM. L-dt: an ongoing phase I/IIa dose-escalation trial in patients with chronic HBV infection (NV-02-001). Gastroenterology 2001; 120 (suppl 1): 572A (abstract).
49. Shaw T., Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology. 32:2000;430-432.
50. Schalm S.W., Heathcote J., Cianciara J., et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 46:2000;562-568.
51. Schiff E., Karayalcin S., Grimm I., et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology. 28S:1998;388A. (abstr).
52. Liaw Y.-F., Tsai S.-L., Chien R.-N., Yeh C.-T., Chu C.-M. Prednisolone priming enhances Th 1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology. 32:2000;604-609.